{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -0.15, "sharesOutstanding": 922958976, "bookValue": 0.055, "fiftyDayAverage": 20.384, "fiftyDayAverageChange": 17.616, "fiftyDayAverageChangePercent": 0.86420715, "twoHundredDayAverage": 21.927, "twoHundredDayAverageChange": 16.073, "twoHundredDayAverageChangePercent": 0.7330232, "marketCap": 350724416, "priceToBook": 690.9091, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "currency": "ILA", "financialCurrency": "USD", "regularMarketOpen": 35.5, "averageDailyVolume3Month": 648600, "averageDailyVolume10Day": 877871, "fiftyTwoWeekLowChange": 24.6, "fiftyTwoWeekLowChangePercent": 1.835821, "fiftyTwoWeekRange": "13.4 - 42.6", "fiftyTwoWeekHighChange": -4.5999985, "fiftyTwoWeekHighChangePercent": -0.10798119, "fiftyTwoWeekLow": 13.4, "fiftyTwoWeekHigh": 42.6, "earningsTimestamp": 1691578740, "earningsTimestampStart": 1691578740, "earningsTimestampEnd": 1691578740, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1175668200000, "priceHint": 2, "marketState": "CLOSED", "regularMarketChange": 6.0, "regularMarketTime": 1683815054, "regularMarketDayHigh": 38.0, "regularMarketDayRange": "34.6 - 38.0", "regularMarketDayLow": 34.6, "regularMarketVolume": 3861169, "regularMarketPreviousClose": 32.0, "bid": 32.1, "ask": 32.4, "bidSize": 2559, "askSize": 429, "fullExchangeName": "Tel Aviv", "regularMarketChangePercent": 18.75, "regularMarketPrice": 38.0, "exchangeTimezoneName": "Asia/Jerusalem", "exchangeTimezoneShortName": "IDT", "gmtOffSetMilliseconds": 10800000, "esgPopulated": false, "exchange": "TLV", "shortName": "BIOLINE RX", "longName": "BioLineRx Ltd.", "messageBoardId": "finmb_5015080", "market": "il_market", "symbol": "BLRX.TA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Modi\u2019in Technology Park", "address2": "2 HaMa\u2019ayan Street", "city": "Modi\u2019in", "zip": "7177871", "country": "Israel", "phone": "972 8 642 9100", "fax": "972 8 642 9101", "website": "https://www.biolinerx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA", "age": 62, "title": "Chief Exec. Officer", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 635000, "fmt": "635k", "longFmt": "635,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Mali  Zeevi CPA, CPA", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 380000, "fmt": "380k", "longFmt": "380,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ella  Sorani", "age": 54, "title": "Chief Devel. Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 457000, "fmt": "457k", "longFmt": "457,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Holly W. May M.B.A.", "age": 60, "title": "Pres of BioLineRx USA", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 328000, "fmt": "328k", "longFmt": "328,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John  Lacey", "title": "Head of Corp. Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Advocate Norman  Kotler", "age": 70, "title": "Internal Enforcement Officer, Gen. Counsel and Corp. Sec.", "yearBorn": 1952, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Liron  Shemesh-Darvish M.B.A., Ph.D.", "title": "Sr. Director & Head of Preclinical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jael  Birenberg M.Sc.", "title": "Sr. Director & Head of RA, QA and PhV", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Tsipi  Keren-Lehrer B.Sc., L.L.B.", "title": "Head of BD & Strategic Advisor", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tami  Rachmilewitz M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}